NCT07230080Active, not recruiting
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
Efficacy and Safety of Sequential TACE-SBRT Combined With Targeted Immunotherapy in Patients With Intermediate to Advanced Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether sequential transarterial chemoembolization (TACE) followed by stereotactic body radiotherapy (SBRT) combined with targeted immunotherapy is effective and safe for patients with intermediate to advanced hepatocellular carcinoma (HCC) who are not eligible for curative treatment such as surgery or liver transplantation. This is a single-center, single-arm, retrospective study. All participants included in the analysis will have received the combined treatment regimen. The main question the study aims to answer is: Can sequential TACE-SBRT combined with targeted immunotherapy improve the objective response rate (ORR) in patients with intermediate to advanced HCC? Interventions Participants in this study have undergone the following treatments: TACE: a minimally invasive procedure to block the blood supply to the tumor while delivering chemotherapy directly. SBRT: a highly precise form of radiation therapy targeting the liver tumor. Targeted immunotherapy: systemic treatment that stimulates the immune system to recognize and attack cancer cells. Participant Population The study includes adult patients diagnosed with intermediate to advanced HCC who were not candidates for curative resection or transplantation.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 17 (actual)
- First submitted
- 27 Sept 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 20 Nov 2025
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07230080
What you commit to
- Study type: Observational
- Participants enrolled: 17
- From 1 Sept 2024 to the primary completion date, 20 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of any malignant disease other than primary liver cancer within 3 years prior to enrollment
Other illness
- History of allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
- Presence of any severe or uncontrolled systemic disease
Lab values
- Any medical history, comorbid condition, treatment, or abnormal laboratory finding that may interfere with study results or hinder full participation, or any other situation that the investigator considers inappropriate for enrollment
Other
- Currently participating in another interventional clinical study
- Investigator's judgment of other potential risks making the patient unsuitable for participation in this study
Who the study is looking for
- Age ≥ 18 years
- Unresectable hepatocellular carcinoma (HCC)
- CNLC stage IIb-IIIb
- Target lesion(s) not previously treated with local therapy
- Child-Pugh class A5-B7 liver function
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2
- At least one measurable lesion based on modified RECIST (mRECIST) criteria
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hosptial Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.